March 17, 2010 – New data released at the American College of Cardiology Scientific Session this week showed continued positive clinical results for the Xience V everolimus-eluting coronary stent.
Four-year results from the SPIRIT II trial were presented by Yoshinobu Onuma, M.D., Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands. In key clinical outcomes such as heart attack, repeat procedure at the target lesion or death, XIENCE V demonstrated a consistent reduction in all these areas out to five years compared to the TAXUS paclitaxel-eluting coronary stent. The SPIRIT II four-year data also demonstrated that there were no new stent thrombosis events for XIENCE V between two and four years.
Data presentations by James Hermiller, M.D., St. Vincent’s Hospital, Indianapolis, Dean Kereiakes, M.D., medical director of The Christ Hospital Heart and Vascular Center, Cincinnati, and Upendra Kaul, M.D., director of cardiology, Fortis Hospital, Noida. India, demonstrated that in complex lesion subsets, XIENCE V exhibited low event rates to the overall population.
Dr. Hermiller presented pooled results on small vessel subsets from the SPIRIT III and SPIRIT IV trials. At one year, XIENCE V outperformed TAXUS in small vessel patients, demonstrating a significant reduction in major adverse cardiac events (4.5 vs. 7.9 percent) and a significant reduction in target lesion failure (4.4 vs. 7.9 percent). There was also a significant 56 percent reduction in target lesion revascularization (TLR) with XIENCE V compared to TAXUS.
Dr. Kereiakes presented a pooled analysis from the SPIRIT III and SPIRIT IV trials, comparing XIENCE V and TAXUS in patients undergoing multivessel stenting. At one year, treatment with XIENCE V resulted in significantly lower rates of adverse events than those treated with TAXUS.
Dr. Kaul presented one-year follow-up data on of complex lesion and patient subgroups from the SPIRIT V Registry. In this registry, XIENCE V achieved single-digit cardiac death, MI and TLR rates in highly complex patient and lesion subgroups such as diabetics, multiple lesions, small vessels, long lesions and bifurcation lesions.
Data on the cost effectiveness of XIENCE V vs. TAXUS were presented by David Cohen, M.D., director of Cardiovascular Research, St. Luke’s Mid-America Heart Institute, Kansas City, Mo. He used data from the SPIRIT IV trial, which found the superior clinical outcomes of XIENCE V had a better economic outcome for both the hospital and healthcare system. At one year, XIENCE V provided improved clinical outcomes and a lower overall medical cost, which saved about $150 to $450 per patient.
Abbott makes the XIENCE V stent (which is also sold under the name PROMUS by Boston Scientific). Boston Scientific produced the TAXUS stent, but discontinued production last fall to concentrate on its second generation TAXUS Liberte paclitaxel-eluting coronary stent.
For more information: www.xiencev.com